SCI REP:HALP对根治性膀胱全切术后膀胱癌患者的预后意义!

2018-01-15 xing.T MedSci原创 发表于威斯康星

由此可见,该研究确定了HALP的预测价值,并且为膀胱癌患者根治性膀胱全切术后提供了一个新的HALPA评分指标。

膀胱癌患者根治性膀胱切除术后结局有所不同,具有异质性。近日,Scientific reports杂志上发表了一篇研究文章,研究人员的目标是评估HALP(血红蛋白、白蛋白、淋巴细胞和血小板)的预后价值,并探讨膀胱癌根治性膀胱全切除术后患者预后的新指标。

在这项回顾性研究中,516例接受根治性膀胱切除术的膀胱癌患者被纳入研究。中位随访时间为37个月(2-99个月)。总生存率降低的危险因素包括年龄、高TNM分期、高美国麻醉医师(ASA)级别和低HALP评分。基于HALP的统计数据图预测准确率较高,相比于TNM分期(C指数为0.76±0.039 vs. 0.708±0.041)。通过将ASA分级和HALP结合,研究人员创建了一个新的HALPA指数评分,并且发现其是生存率降低的独立危险因素(HALPA评分=1,风险比为1.624,95%可信区间为1.139-2.314,P=0.007;HALPA评分=2,风险比为3.471,95%可信区间为1.861-6.472,P<0.001)。

由此可见,该研究确定了HALP的预测价值,并且为膀胱癌患者根治性膀胱全切术后提供了一个新的HALPA评分指标。

在线使用:膀胱癌根治性术后的预后评估(基于HALP的评分)

原始出处:

Ding Peng,et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy.Scientific reports. 2018. https://www.nature.com/articles/s41598-018-19146-y

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-04-19 jiekemin
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-28 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-17 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-16 大爰

    学习了谢谢分享!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2035998, encodeId=fc3b203599863, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Apr 19 20:39:00 CST 2018, time=2018-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282838, encodeId=f05b2828388a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Jan 28 09:35:44 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546236, encodeId=a91b1546236db, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586089, encodeId=d1981586089e0, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Wed Jan 17 11:39:00 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279022, encodeId=b8f22e902294, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Tue Jan 16 09:10:42 CST 2018, time=2018-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278848, encodeId=7f312e884880, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Jan 15 22:55:51 CST 2018, time=2018-01-15, status=1, ipAttribution=)]
    2018-01-15 天涯183

    非常好的文章.学习了

    0

相关资讯

JAMA SURGERY:新辅助化疗联合放疗与单纯新辅助化疗对比治疗局部晚期膀胱癌

局部晚期膀胱癌根治性切除后局部治疗失败常见,与患者发病率和死亡率增高有关。新辅助放疗可以减少局部治疗失败可能,但尚未在化疗领域进行研究。JAMA SURGERY近期发表了一篇文章,研究放疗联合化疗与新辅助化疗相比是否可以改善患者局部无复发生存情况。

J Urol:一种检测膀胱癌的灵敏度比尿细胞学更高的90分钟一体化尿液分析方法。

尽管敏感性不佳,但尿细胞学通常作为膀胱镜检查诊断膀胱癌的辅助手段。本研究的目标是开发一种非侵入性,快速检测膀胱癌的分子诊断测试,它比尿细胞学检测的灵敏度更高,同时又能够保持足够的特异性。

NCCN临床实践指南:膀胱癌(2018.V1)

2018年1月,美国国家综合癌症网络(NCCN)发布了膀胱癌指南2018年第1版,指南主要内容包括: 指南更新摘要 膀胱癌 临床表现和初始评估 非侵袭性或Tis,初步评估/手术治疗 肌层侵袭或转移,初步评估/手术治疗,额外检查 膀胱/移行细胞癌影像学检查 手术治疗原则 病理检查原则 非肌层浸润性膀胱癌复发概率 膀胱癌:非肌层以及移行细胞变异组织学 术后随访 膀胱灌注治疗原则 化疗原则 侵袭性疾病放

晚期膀胱癌5年生存率不足5%,肿瘤免疫治疗或带来希望

据估计,膀胱癌已经占到我国泌尿系肿瘤发病率的第一位,大约10%的膀胱癌患者在诊断时就已经是晚期,且膀胱癌患者通常预后较差,晚期患者的5年生存率不足5%。中国膀胱癌联盟主席、中华医学会泌尿外科分会候任主任委员、中山大学孙逸仙纪念医院黄健教授指出,我国膀胱癌现有的治疗方案主要以化疗为主,但是疗效有限,长期使用容易产生耐药,加上严重的副反应极大地影响患者的生活质量,而且预后仍然不够理想。“有50%的患者

CLIN CANCER RES:放射性诺模图术前预测膀胱癌淋巴结转移

CLIN CANCER RES近期发表了一篇文章,研究放射性诺模图在膀胱癌淋巴结转移术前诊断中的应用。

JAMA Surg:局部晚期膀胱癌:RC后辅助三明治化疗+放疗vs仅辅助化疗

2017年11月,发表在《JAMA Surg》的一项由埃及和美国科学家进行的随机2期试验,比较了根治性膀胱切除术(RC)后辅助三明治化疗+放疗(RT)和仅辅助化疗治疗局部晚期膀胱癌(LABC)的效果。

Cell Mol Life Sci:蛋白激酶D抑制剂CRT0066101通过在G2 / M阻断细胞周期抑制膀胱癌细胞体外和异种移植物的生长。

在本研究中,作者发现CRT0066101在体外抑制了四种膀胱癌细胞系的增殖和迁移,并且证明CRT0066101能够阻断膀胱癌小鼠侧腹异种移植模型中肿瘤的生长。

CLIN CANCER RES:PI3K通路作为膀胱癌的潜在治疗靶点

超过40%的膀胱尿路上皮癌中出现PI3K通路激活。CLIN CANCER RES近期发表了一篇文章,研究靶向PI3K通路药物的治疗潜力及耐药机制。

Npj Genomic Med:在早期膀胱癌中,环状RNA表达是丰富的并且与侵入性相关

由于越来越多的证据表明环状RNAs在致瘤过程中具有作用,环状RNAs(cirRNAs)在各种癌症类型中的功能和生物标记潜力越来越成为当前研究的一个热点。最近,有研究人员分析了cirRNAs在457个肿瘤中的表达情况,另外,这些肿瘤来源自那些患有非肌肉侵入性膀胱癌(NMIBC)病人。研究人员发现,一些高表达的cirRNAs具有保守的核心剪接位点,并且与Alu重复相关,还富含SCEs以及microRN

CLIN CANCER RES:BMP4诱导M2巨噬细胞极化促进膀胱癌进展

膀胱癌目前是一道临床难题,也是社会性难题。诊断时,大部分病人表现为非肌层浸润肿瘤,复发率高,可以进展为肌层浸润肿瘤并转移。膀胱组织中的骨形成蛋白(BMP)依赖信号通路可以促进尿路上皮细胞分化调节尿路上皮稳态。但是BMP配体在膀胱癌中的作用尚不清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。